Ethanol-Induced Alterations in Pancreatic and Gastric Hormone Secretion Promotes Hepatic Steatosis
AASLD LiverLearning®, Karuna Rasineni, 144129
Longitudinal changes in peripheral CD4+ regulatory T cells upon treatment of chronic hepatitis C with direct-acting antivirals
AASLD LiverLearning®, Bettina Langhans, 144385
Analysis of immune responses in hepatocellular carcinoma patients vaccinated with alpha-fetoprotein-derived peptides
AASLD LiverLearning®, Eishiro Mizukoshi, 144130
CXCR3-high/CD81-low B cells in Early Acute HCV Infection Correlates with Severity of Liver Inflammation
AASLD LiverLearning®, Mengfei Liu, 144386
Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)
AASLD LiverLearning®, Josep Llovet, 144131
Hepatitis C non-structural proteins 5 & 5B upregulate MHC class I to evade NK cytotoxicity
AASLD LiverLearning®, Thomas Pembroke, 144387
HCV-HIV Co-Infected Female Patients Do Not Exhibit Immunological Deterioration & Liver Disease Progression With HAART Therapy: A 5 Years Retrospective Observational Study
AASLD LiverLearning®, Shady Guirguis, 144388
Immunological characteristics of the tumor-associated antigens in patients with cholangiocarcinoma
AASLD LiverLearning®, Akihiko Kida, 144145
The FXR/TGR5 Dual Agonist INT-767 Reduces NAFLD Activity Score and Fibrosis Stage and Improves Plasma and Hepatic Lipid Profiles in the GUBRA-AMLN Mouse Model of Diet-induced and Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Jonathan Roth, 144401
Usefulness of modified Japan Integrated Staging (JIS) score using albumin-bilirubin (ALBI) grade as a prognostic scoring system for hepatocellular carcinoma: analysis with 2584 Japanese patients
AASLD LiverLearning®, Hirofumi Izumoto, 144146
Live cell imaging of hepatocyte cytosolic NADH/NAD+ ratio in mouse liver slices
AASLD LiverLearning®, Ricard Masia, 144402
Growth Hormone and Hepatocellular Carcinoma
AASLD LiverLearning®, Manal Hassan, 144147
TRAIL deficiency protects against fibrosis in murine nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Petra Hirsova, 144403
Hepatic Vagus Nerve Regulates Inflammatory Response of Kupffer Cell via α7 Nicotinic Acetylcholine Receptor in Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Takahiro Nishio, 144404
Decreased liver volume is an independent predictor of hepatocellular carcinoma in chronic hepatitis B patients on entecavir therapy
AASLD LiverLearning®, Chung Seop Lee, 144161
Sirt6 deletion in liver promotes NASH development by downregulation of Nrf2 in mice fed a high-fat, high-fructose diet.
AASLD LiverLearning®, Sun-O Ka, 144417
Translating the ABC-02 trial into daily practice: Outcome of palliative treatment in patients with advanced biliary tract cancer treated with gemcitabine and cisplatin
AASLD LiverLearning®, Jeroen van Vugt, 144162
Non-alcoholic fatty liver disease derails antiviral immunity in murine viral hepatitis
AASLD LiverLearning®, Ting Wu, 144418
The efficacy and safety of doxorubicin-eluting bead transarterial chemoembolization over sorafenib for unresectable hepatocellular carcinoma with portal vein invasion
AASLD LiverLearning®, Hyeki Cho, 144163
Comparisons of metabolically healthy and unhealthy obesity in biopsy-proven nonalcoholic fatty liver disease patients.
AASLD LiverLearning®, ILGUEN PARK, 144419
Genome-scale Metabolic Models Reveal Metabolic Alterations in a Human Surrogate Model of Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Stephen Hoang, 144420
The GALAD serological model may permit earlier diagnosis of hepatocellular carcinoma in a screened cirrhotic population: a re-analysis of a prospective trial
AASLD LiverLearning®, Hiroyuki Yamada, 144177
EDP-305, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits high Potency and Efficacy In Vitro and In Vivo
AASLD LiverLearning®, Lijuan Jiang, 144433
Gene Network Analysis Reveals a Novel 22-Gene Signature of Carbon Metabolism in Hepatocellular Carcinoma
AASLD LiverLearning®, jinqiang zhang, 144178
Pirfenidone LP activates PPARα and LXRα and results in decreased expression of proinflammatory cytokines and improvement of NASH features induced by high fat/carbohydrate diet
AASLD LiverLearning®, José Macías-Barragán, 144434
Liver microRNA hsa-miR-125a-5p exerts an oncosuppressor effect on hepatocellular carcinoma (HCC) regulating the expression of MMP11, c-Raf and SIRT7.
AASLD LiverLearning®, Nicola Coppola, 144179
Vitamin D3 up-regulated protein 1-depentant autophagy and fatty acid oxidation attenuate liver steatosis
AASLD LiverLearning®, HYO JUNG KWON, 144435
Angiogenesis in the Pathogenesis of Non-Alcoholic Fatty Liver Diseases (NAFLD)
AASLD LiverLearning®, Savneet Kaur, 144436
Patients with Nonalcoholic Steatohepatitis Cirrhosis Are Significantly Less Likely To Receive Appropriate Screening for Hepatocellular Carcinoma Compared to Patients with Chronic Hepatitis C Virus Cirrhosis
AASLD LiverLearning®, Hesam Tavakoli, 144193
The Mixed Lineage Kinase Inhibitor 3 URMC-009 Attenuates Established Murine Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Brittany Freeman, 144449
Platinum-based transhepatic arterial chemotherapy using a combination of miriplatin and CDDP powder in patients with hepatocellular carcinoma
AASLD LiverLearning®, Kohei Ogawa, 144194
Rapid development of NASH in FLS-ob/ob mice and its application for anti-fibrosis evaluation, -Effects of pioglitazone on liver fibrosis and metabolic parameters-
AASLD LiverLearning®, Tadateru Hamada, 144450
Therapeutic option as an alternative strategy for a solitary (3-5 cm) hepatocellular carcinoma; an analysis of a nationwide cancer registry database
AASLD LiverLearning®, Young-Joo Jin, 144195
involvement of type 4 porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.
AASLD LiverLearning®, Takashi Nakahara, 144451
Intervention with the CCR2 inhibitor propagermanium attenuates insulin resistance, adipose tissue inflammation and NASH development
AASLD LiverLearning®, Kanita Salic, 144452
Safety, Tolerability and Pharmacokinetics of L-Ornithine Phenylacetate in Patients with Acute Liver Injury/Failure
AASLD LiverLearning®, Richard Stravitz, 154954
A Novel Single Daily Fixed Dose Combination of Sofosbuvir400 mg + Ribavirin1000mg + EGCG400 mg is Superior to the Standard of Care as an Anti-Viral and Safer Causing less Hemolysis in Patients with Chronic Hepatitis C
AASLD LiverLearning®, Gamal Shiha, 154955
Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4)
AASLD LiverLearning®, Tarek Hassanein, 154956
The Substantial Relationship between Hepatitis B (HBV) and Hepatocecullar carcinoma (HCC): A cross-sectional analysis of HBV and HCC rates from the World Health Organization (WHO) database
AASLD LiverLearning®, Eduardo Rodriguez, 144209
Butyrate induces ROS-mediated apoptosis via modulation of miR-22/SIRT-1 pathway in Hepatoma cells.
AASLD LiverLearning®, Kishor Pant, 144465
Surgical Management of Recurrent Intrahepatic Cholangiocarcinoma; Predictors, Adjuvant Chemotherapy, and Surgical Therapy for Recurrence: A Multi-Institutional Study by the Kyushu Study Group of Liver Surgery
AASLD LiverLearning®, Yo-ichi Yamashita, 144210
Apg2 is a key determinant of hepatic steatosis by regulating AMPK activity
AASLD LiverLearning®, Hiroshi Ishiba, 144466
Metabolic disorders across hepatocellular carcinoma in Italy.
AASLD LiverLearning®, Filomena Morisco, 144211
The GLP-1 analogue, liraglutide, reduces NAFLD Activity Score and Fibrosis Stage and improves metabolic parameters in a diet-induced obese mouse model of biopsy-confirmed nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Kirstine Tølbøl, 144467
YH25724, a novel long-acting GLP-1/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models
AASLD LiverLearning®, JUN HWAN KIM, 154970
Spexin, a novel regulator of lipid & carbohydrate metabolism, is a potential therapeutic for obesity, type 2 diabetes mellitus, & non-alcoholic fatty liver disease.
AASLD LiverLearning®, Paul Berk, 154971
Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Sheila DeWitt, 154972
ALBI grade versus Child-Pugh grade as a grading system for liver function in patients with hepatocellular carcinoma
AASLD LiverLearning®, Seong Kyun Na, 144225
The effect of interferon-free therapy on tumor recurrence in HCV patients with treatment history of hepatocellular carcinoma
AASLD LiverLearning®, Yasuhiro Tsuda, 144226
Rosuvastatin prevents the development of hepatocellular carcinoma in mice with nonalcoholic fatty liver disease.
AASLD LiverLearning®, Keisuke Yokohama, 144482
Clinical Characteristics, Management and Outcomes of Patients with Hepatocellular Carcinoma in Africa: Multi-Country Study from the Africa Liver Cancer Consortium.
AASLD LiverLearning®, Ju Dong Yang, 144227
DPP4 Inhibitor Suppressed Warburg-Dickens Pathway and HCC Progression in a Mouse Model of NASH: A Metabolomic Analysis
AASLD LiverLearning®, Takumi Kawaguchi, 144483
Iron chelator suppresses hepatocarcinogenesis through mitophagy induction in STAM® mice
AASLD LiverLearning®, Yuhichi Hara, 144484
Hepatocellular Carcinoma Screening in High-Risk Populations in the United States
AASLD LiverLearning®, Manal Hassan, 144241
Intraductal papillary neoplasm of the bile duct: histological and molecular analysis of 27 patients
AASLD LiverLearning®, Yoshiki Naito, 144242
Exosome Derived from Palmitic Acid-treated Hepatocytes Activates Hepatic Stellate Cells
AASLD LiverLearning®, Young-Sun Lee, 144498
Education Level and Household Income is Significantly Associated with Disparities in Hepatocellular Carcinoma Stage at Diagnosis and Treatment Received
AASLD LiverLearning®, Johnathan Ha, 144243
ER Stress Regulates Autophagy and Protein Secretion through IBTKα during the Pathogenesis of Non-Alcoholic Steatohepatitis
AASLD LiverLearning®, Jeffrey Willy, 144499
Macrophage-Specific Deletion of SHP Exacerbates Diet-induced Nonalcoholic steatohepatitis in Mice
AASLD LiverLearning®, Roeland Zoutendijk, 144500
Time to Initial Treatment of Hepatocellular Carcinoma in an Urban Hospital
AASLD LiverLearning®, Tae Hoon Lee, 144256
Low long term tumor recurrence and mortality rates in patients transplanted for hepatocellular carcinoma listed with low native MELD scores
AASLD LiverLearning®, Heather O'Dell, 144257
The prognostic impact of TERT promotor mutations and rs2853669 single nucleotide polymorphism combination in hepatocellular carcinoma
AASLD LiverLearning®, Helder Cardoso, 144258
Liver Transplantation for Hepatocellular carcinoma: Results from a Multicenter Cohort from Latin America.
AASLD LiverLearning®, Federico Piñero, 144259
Novel LXR inverse agonists demonstrate anti-steatotic effects in human hepatocytes and in a rat model of NAFLD
AASLD LiverLearning®, Claus Kremoser, 144515
In Hepatocytes, DNA Methylation and Hydroxymethylation Are Altered in Response to Oleic Acid Exposure: A Potential Mechanism for Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Zobair Younossi, 144516
Hepatic Sonic Hedgehog (SHH) Expression Measured by Computer Assisted Morphometry Correlates Histologic Features of Non-Alcoholic Steatohepatitis (NASH) and Circulating Markers of Apoptosis and Cell Injury
AASLD LiverLearning®, Zobair Younossi, 144517
Extemporanous HR-MAS-NMR metabolomic profiling of back-table liver grafts predicts early graft dysfunction
AASLD LiverLearning®, Francois Faitot, 144272
Projections of non-alcoholic steatohepatitis related liver transplantation waitlist additions
AASLD LiverLearning®, Neehar Parikh, 144273
Higher Mortality Rate after Liver Transplantation in Non-Obese Patients: Is This another indication of the Obesity Paradox?
AASLD LiverLearning®, Elnaz Jafarimehr, 144274
Graft quality matters: KDPI is more predictive of survival than SLK compared with liver transplant alone in a propensity score matched cohort
AASLD LiverLearning®, Colleen Jay, 144275
Outcomes for patients listed for liver transplantation with a low Model for End-Stage Liver Disease (MELD) score
AASLD LiverLearning®, Arjmand Mufti, 144288
Sarcopenia in children awaiting liver transplantation.
AASLD LiverLearning®, Eberhard Lurz, 144289
A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma
AASLD LiverLearning®, Jeroen van Vugt, 144290
Multicenter Study on Down-staging of Hepatocellular Carcinoma for Liver Transplantation: Is Down-staging Failure due to the Tumor or the Long Waiting time?
AASLD LiverLearning®, Neil Mehta, 144291
Glucose homeostasis in cirrhosis: accuracy of hemoglobin a1c and potential usefulness of continuous glucose monitoring
AASLD LiverLearning®, Andres Duarte-Rojo, 144304
Chronic Opioid Therapy Independently Predicts Readmissions Regardless of HE in a Prospective Cohort of Cirrhotic Patients
AASLD LiverLearning®, Chathur Acharya, 144305
Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study
AASLD LiverLearning®, Jonathan Stine, 144306
Critical Flicker Frequency predicts progression among stages of cirrhosis
AASLD LiverLearning®, Javier Ampuero, 144307
Pulse Oximetry is a Poor Screening Test for Hepatopulmonary Syndrome in Liver Transplant Candidates
AASLD LiverLearning®, Kimberly Forde, 144320
Hyperosmolality is Independently Associated with Severity of Hepatic Encephalopathy in Patients Admitted to Intensive Care Units with Acutely Decompensated Liver Function
AASLD LiverLearning®, Eric Liotta, 144321
How to define splenomegaly in the diagnosis of liver cirrhosis? : Significance of splenic volume measurement using ultrasonography
AASLD LiverLearning®, sang gyune kim, 144322
Sleep Abnormalities are More Prominent Among Patients with Compensated Cirrhosis with Portosystemic Collaterals
AASLD LiverLearning®, Maya Balakrishnan, 144323
Is a simple screening strategy for minimal HE using Stroop Encephalapp enough to predict overt hepatic encephalopathy occurrence?
AASLD LiverLearning®, Andres Duarte-Rojo, 144336
Patients with cirrhosis have highly increased coronary arteriosclerosis
AASLD LiverLearning®, Karen Danielsen, 144337
Availability of contrast-enhanced ultrasonography for the evaluation of partial splenic embolization in cirrhotic patients with hypersplenism
AASLD LiverLearning®, Takashi Matsuda, 144338
The Fatigue of Chronic Liver Disease is Associated with Altered Circadian Rhythm of Cortisol
AASLD LiverLearning®, Michele Tana, 144339
Hepatitis due to HBV reactivation in chronic hepatitis B and C co-infected Chinese treated with direct-acting antivirals
AASLD LiverLearning®, Weicheng Wang, 144352
Corticosteroids are the only remaining pharmacological option for severe alcoholic hepatitis: a meta-analysis of individual data on 1974 patients.
AASLD LiverLearning®, Philippe MATHURIN, 144097
Transcriptome wide characterization of polarized macrophages in the setting of HCV/HIV co-exposure
AASLD LiverLearning®, Shadi Salloum, 144353
Assessment of nutritional status through bioelectrical impedance is a key determinant of outcome in alcoholic hepatitis: a prospective study
AASLD LiverLearning®, Laurent Spahr, 144098
COP II trafficking promotes hepatitis C virus entry through claudin-1
AASLD LiverLearning®, Peiqi Yin, 144354
Alcohol Misuse is Associated with Intestinal Mucosal Dysbiosis and Stool Metabolomic Alterations In Human Cirrhosis
AASLD LiverLearning®, Jasmohan S. Bajaj, 144099
Selenoprotein P, a liver-derived secretory protein, regulates RIG-I-mediated innate immunity in hepatocytes
AASLD LiverLearning®, Kazuhisa Murai, 144355
HCV Cure: Increases Body Weight and Liver Fat Content
AASLD LiverLearning®, Isaac Wasserman, 144368
Hepatic SIRT1 is Dispensable for Adiponectin-Mediated Amelioration of Bile Acid Metabolism Abnormalities and Liver Dysfunction in Ethanol-Fed Mice
AASLD LiverLearning®, Min You, 144113
The Sofosbuvir (SOF) and Velpatasvir (VEL) Regimen is Associated with High Efficacy and Improvement of Patient-Reported Outcomes (PROs) in Patients Co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV): The Data from ASTRAL-5
AASLD LiverLearning®, Zobair Younossi, 144369
The chemical chaperone 4-phenylbutyric acid prevents ethanol-induced liver injury in diabetic KK-Ay mice
AASLD LiverLearning®, Maiko Suzuki, 144114
A liver-derived secretory protein, LECT2, enhances the innate immune response and suppresses HCV replication
AASLD LiverLearning®, Takayoshi Shirasaki, 144370
Acute-on-chronic alcohol exposure using the ‘NIAAA model’ concomitantly damages the liver and lung
AASLD LiverLearning®, Lauren Poole, 144115
Decreased NKG2D on Natural Killer Cells After IFN-free DAAs Correlates to Early HCC Emergence in Chronic Hepatitis C
AASLD LiverLearning®, Po-Sung Chu, 144371